Conferences

ecancer travels so that you don't have to. Explore the latest conference coverage in global oncology and find out where we are going next.
Bookmark and Share

2012 ASCO Annual Meeting

6 Dec 2011
AC Hotel Firenze, Florence, Italy
The role of genomic tests in personalised medicine for colon cancer
Prof David Kerr - Oxford Clinical Trials Research Unit, Oxford, UK
The role of genomic tests in personalised medicine for colon cancer ( Prof David Kerr - Oxford Clinical Trials Research Unit, Oxford, UK )
29 Aug 2012
Phase 1-2 results for oral proteasome inhibitor MLN9708 for multiple myeloma (Sp...
Dr Rafael Fonseca – Mayo Clinic, Arizona, USA
Phase 1-2 results for oral proteasome inhibitor MLN9708 for multiple myeloma (Spanish) ( Dr Rafael Fonseca – Mayo Clinic, Arizona, USA )
20 Jun 2012
BRCA carrier status as a prognostic factor for prostate cancer
Dr Elena Castro - The Institute of Cancer Research, Sutton, UK
BRCA carrier status as a prognostic factor for prostate cancer ( Dr Elena Castro - The Institute of Cancer Research, Sutton, UK )
20 Jun 2012
Retrospective study of optimal treatment for intermediate-risk testes cancer
Dr Constantine Albany - Indiana University, Indianapolis, USA
Retrospective study of optimal treatment for intermediate-risk testes cancer ( Dr Constantine Albany - Indiana University, Indianapolis, USA )
20 Jun 2012
Combined chemo-radiation extends survival for anaplastic oligodendroglial tumour...
Prof Martin van den Bent - Erasmus University Medical Center, Rotterdam, The Net...
Combined chemo-radiation extends survival for anaplastic oligodendroglial tumours ( Prof Martin van den Bent - Erasmus University Medical Center, Rotterdam, The Netherlands )
20 Jun 2012
Effects of age on treatment and outcomes in women with stage IB-IIB cervical can...
Dr Don Dizon – Brown University, Providence, USA
Effects of age on treatment and outcomes in women with stage IB-IIB cervical cancer ( Dr Don Dizon – Brown University, Providence, USA )
19 Jun 2012
Insight in to the EMILIA trial and systemic challenges with neoadjuvant therapy
Dr Erica Mayer - Dana-Farber Cancer Institute, Boston, MA, USA
Insight in to the EMILIA trial and systemic challenges with neoadjuvant therapy ( Dr Erica Mayer - Dana-Farber Cancer Institute, Boston, MA, USA )
19 Jun 2012
MEK inhibitor, trametinib, improves progression free survival in melanoma
Dr Caroline Robert – Institute Gustave Roussy, Paris, France
MEK inhibitor, trametinib, improves progression free survival in melanoma ( Dr Caroline Robert – Institute Gustave Roussy, Paris, France )
18 Jun 2012
SUCCEED trial: Maintenance treatment in advance soft tissue sarcoma
Dr Jean Yves-Blay - University Claude Bernard, Lyon, France
SUCCEED trial: Maintenance treatment in advance soft tissue sarcoma  ( Dr Jean Yves-Blay - University Claude Bernard, Lyon, France )
18 Jun 2012
Drug development in small cell and non-small cell lung cancer
Dr Leora Horn - Vanderbilt-Ingram Cancer Center, Nashville, USA
Drug development in small cell and non-small cell lung cancer ( Dr Leora Horn - Vanderbilt-Ingram Cancer Center, Nashville, USA  )
18 Jun 2012
ASCO 2012 Drug Development Research Professorship
Dr Alex Adjei - Roswell Park Cancer Institute, Las Vegas, USA
ASCO 2012 Drug Development Research Professorship ( Dr Alex Adjei - Roswell Park Cancer Institute, Las Vegas, USA )
18 Jun 2012
Early phase trial of ibrutinib for chronic lymphocytic leukaemia
Dr Samantha Jaglowski - Ohio State University Medical Center, Columbus, USA
Early phase trial of ibrutinib for chronic lymphocytic leukaemia ( Dr Samantha Jaglowski - Ohio State University Medical Center, Columbus, USA )
18 Jun 2012
Novel PET tracers and their future use in assessment of response to treatment
Dr Andrei Iagaru – Stanford University, CA, USA
Novel PET tracers and their future use in assessment of response to treatment ( Dr Andrei Iagaru – Stanford University, CA, USA )
17 Jun 2012
Treating metastatic melanoma with vemurafenib
Dr Paul Chapman – Memorial Sloan-Kettering Cancer Center, New York, USA
Treating metastatic melanoma with vemurafenib   ( Dr Paul Chapman – Memorial Sloan-Kettering Cancer Center, New York, USA )
15 Jun 2012
Clinical trials for rare tumour types
Dr William Tap – Memorial Sloan-Kettering Cancer Center, New York, USA
Clinical trials for rare tumour types ( Dr William Tap – Memorial Sloan-Kettering Cancer Center, New York, USA )
15 Jun 2012
Role of family history and genetic testing in diagnosis
Dr Marie Wood – University of Vermont, Burlington, USA
Role of family history and genetic testing in diagnosis  ( Dr Marie Wood – University of Vermont, Burlington, USA )
15 Jun 2012
First line treatment against metastatic breast cancer
Dr Karen Gelmon – BC Cancer Agency, Vancouver, Canada
First line treatment against metastatic breast cancer ( Dr Karen Gelmon – BC Cancer Agency, Vancouver, Canada )
15 Jun 2012
Early phase 1/2 results with oral proteasome inhibitor MLN9708 in myeloma
Dr Sagar Lonial – Emory University, Atlanta, USA
Early phase 1/2 results with oral proteasome inhibitor MLN9708 in myeloma ( Dr Sagar Lonial – Emory University, Atlanta, USA )
15 Jun 2012
Effects of panitumumab against oesophageal-gastro cancer and carcinomas
Dr Tom Waddell – Royal Marsden Hospital, Sutton, UK
Effects of panitumumab against oesophageal-gastro cancer and carcinomas ( Dr Tom Waddell – Royal Marsden Hospital, Sutton, UK )
15 Jun 2012
Effects of lapatinib and trastuzumab on progression free survival
Dr Nancy Lin – Dana Farber Cancer Institute, Boston, MA, USA
Effects of lapatinib and trastuzumab on progression free survival ( Dr Nancy Lin – Dana Farber Cancer Institute, Boston, MA, USA )
15 Jun 2012
Decision making in surgical breast cancer treatment
Dr Monica Morrow – Memorial Sloan-Kettering Cancer Center, New York, NY, USA
Decision making in surgical breast cancer treatment ( Dr Monica Morrow – Memorial Sloan-Kettering Cancer Center, New York, NY, USA )
15 Jun 2012
Regorafenib effective for GISTs that progress due to resistance to approved targ...
Dr George Demetri - Dana-Farber Cancer Institute, Boston, USA
Regorafenib effective for GISTs that progress due to resistance to approved targeted therapies ( Dr George	 Demetri - Dana-Farber Cancer Institute, Boston, USA )
13 Jun 2012
ASCO 2012: Advances in myeloma
Dr Philippe Moreau - Centre Hospitalier Universitaire de Nantes, France; Prof Ga...
ASCO 2012: Advances in myeloma ( Dr Philippe Moreau - Centre Hospitalier Universitaire de Nantes, France; Prof Gareth Morgan - Royal Marsden Hospital, UK )
12 Jun 2012
ASCO 2012: advances in high-risk prostate cancer; neoadjuvant abiraterone
Dr Chris Parker - Royal Marsden Cancer Centre, UK; Dr Mary-Ellen Taplin, Dana-Fa...
ASCO 2012: advances in high-risk prostate cancer; neoadjuvant abiraterone ( Dr Chris Parker - Royal Marsden Cancer Centre, UK; Dr Mary-Ellen Taplin, Dana-Farber Cancer Institute, USA )
12 Jun 2012
ASCO 2012: Metastatic castration-resistant prostate cancer; abiraterone acetate ...
Dr Chris Parker - Royal Marsden Cancer Centre, UK; Dr Karim Fizazi from Institut...
ASCO 2012: Metastatic castration-resistant prostate cancer; abiraterone acetate COU-AA-302 study ( Dr Chris Parker - Royal Marsden Cancer Centre, UK; Dr Karim Fizazi from Institut Gustave Roussy, France )
12 Jun 2012
ASCO 2012: Advances in pre-operative care in high-risk mCRCP
Dr Chris Parker - Royal Marsden Cancer Centre, UK; Prof Eleni Efstathiou - MD An...
ASCO 2012: Advances in pre-operative care in high-risk mCRCP ( Dr Chris Parker - Royal Marsden Cancer Centre, UK; Prof Eleni Efstathiou - MD Anderson Cancer Centre, USA )
12 Jun 2012
ASCO 2012: Advances in lymphoma; bendamustine combination in indolent lymphoma
Prof John Gribben - Barts & The London Trust Cancer Centre, UK; Prof Mathias Rum...
ASCO 2012: Advances in lymphoma; bendamustine combination in indolent lymphoma ( Prof John Gribben - Barts & The London Trust Cancer Centre, UK; Prof Mathias Rummel - University Hospital Giessen, Germany )
12 Jun 2012
ASCO 2012: Advances in metastatic castration-resistant prostate cancer; first-li...
Dr Chris Parker - Royal Marsden Cancer Centre, London, UK; Prof Stéphan Oudard -...
ASCO 2012: Advances in metastatic castration-resistant prostate cancer; first-line cabazitaxel ( Dr Chris Parker - Royal Marsden Cancer Centre, London, UK; Prof Stéphan Oudard - Hôpital Européen Georges Pompidou, France )
12 Jun 2012
ASCO 2012: Advances in metastatic castration-resistant prostate cancer with abir...
Dr Karim Fizazi - Institut Gustave Roussy, France; Dr Oscar Goodman - Nevada Can...
ASCO 2012: Advances in metastatic castration-resistant prostate cancer with abiraterone ( Dr Karim Fizazi - Institut Gustave Roussy, France; Dr Oscar Goodman - Nevada Cancer Institute, USA )
12 Jun 2012
President's overview of ASCO 2012
Dr Michael Link - Stanford School of Medicine, California, USA
President's overview of ASCO 2012 ( Dr Michael Link - Stanford School of Medicine, California, USA )
4 Jun 2012
Drug shortage impact on cancer care and efforts to resolve the issue
Dr Sandra Kweder - US Food and Drug Administration
Drug shortage impact on cancer care and efforts to resolve the issue ( Dr Sandra Kweder - US Food and Drug Administration )
4 Jun 2012
Patient perspective on drug shortages
Dr Michael Link - Stanford University School of Medicine, California, USA
Patient perspective on drug shortages ( Dr Michael Link - Stanford University School of Medicine, California, USA )
4 Jun 2012
Recommendations for averting drug shortages
Dr Richard Schilsky - University of Chicago, USA
Recommendations for averting drug shortages ( Dr Richard Schilsky - University of Chicago, USA )
4 Jun 2012
FDA's comments on drug shortages
Dr Charles Penley - Tennessee Oncology, USA
FDA's comments on drug shortages ( Dr Charles Penley - Tennessee Oncology, USA )
4 Jun 2012
New BRAF inhibitor dabrafenib delays disease progression in advanced melanoma
Dr Axel Hauschild - Universitaetsklinikum Schleswig-Holstein, Germany
New BRAF inhibitor dabrafenib delays disease progression in advanced melanoma ( Dr Axel Hauschild - Universitaetsklinikum Schleswig-Holstein, Germany )
4 Jun 2012
Increased risk of breast cancer among young women treated with radiation as a ch...
Dr Chaya Moskowitz - Memorial Sloan-Kettering Cancer Center, New York, USA
Increased risk of breast cancer among young women treated with radiation as a child ( Dr Chaya Moskowitz - Memorial Sloan-Kettering Cancer Center, New York, USA )
4 Jun 2012
New MEK inhibitor, trametinib, improves survival in advanced melanoma
Dr Caroline Robert - Institut Gustave Roussy, Villejuif, France
New MEK inhibitor, trametinib, improves survival in advanced melanoma ( Dr Caroline Robert - Institut Gustave Roussy, Villejuif, France )
4 Jun 2012
First effective treatment for chemotherapy-induced peripheral neuropathy
Dr Ellen Lavoie Smith - University of Michigan, Ann Arbor, USA
First effective treatment for chemotherapy-induced peripheral neuropathy ( Dr Ellen Lavoie Smith - University of Michigan, Ann Arbor, USA )
4 Jun 2012
Afatinib delays progression of advanced lung adenocarcinomas
Dr James Yang - National Taiwan University Hospital, Taipei
Afatinib delays progression of advanced lung adenocarcinomas ( Dr James Yang - National Taiwan University Hospital, Taipei )
4 Jun 2012
Costly drugs versus paclitaxel as first line therapy for locally advanced or met...
Dr Hope Rugo - University of California San Francisco, USA
Costly drugs versus paclitaxel as first line therapy for locally advanced or metastatic breast cancer ( Dr Hope Rugo - University of California San Francisco, USA )
4 Jun 2012
Routine molecular testing of non-small cell lung cancers in community settings
Dr Thomas Zander - University Hospital Cologne, Germany
Routine molecular testing of non-small cell lung cancers in community settings ( Dr Thomas Zander - University Hospital Cologne, Germany )
4 Jun 2012
Regorafenib effective for GISTs that progress due to resistance to approved targ...
Dr George Demetri - Dana Farber Cancer Institute, Boston, USA
Regorafenib effective for GISTs that progress due to resistance to approved targeted therapies ( Dr George Demetri - Dana Farber Cancer Institute, Boston, USA )
4 Jun 2012
Better taking of family histories and referral to genetic counselling
Dr Marie Wood - University of Vermont, Burlington, USA
Better taking of family histories and referral to genetic counselling ( Dr Marie Wood - University of Vermont, Burlington, USA )
4 Jun 2012
EMILIA trial: Trastuzumab emtansine improves progression-free survival in HER2-p...
Dr Kimberly Blackwell - Duke University Medical Center, Durham, USA
EMILIA trial: Trastuzumab emtansine improves progression-free survival in HER2-positive breast cancer ( Dr Kimberly Blackwell - Duke University Medical Center, Durham, USA )
3 Jun 2012
Increased progression-free survival in advanced lung cancer with afatinib
Dr James Yang - National Taiwan University Hospital Taipei, Taiwan
Increased progression-free survival in advanced lung cancer with afatinib  ( Dr James Yang - National Taiwan University Hospital Taipei, Taiwan )
3 Jun 2012
Intermittent hormonal therapy versus continuous therapy for advanced prostate ca...
Dr Maha Hussain - University of Michigan, Ann Arbor, USA
Intermittent hormonal therapy versus continuous therapy for advanced prostate cancer ( Dr Maha Hussain - University of Michigan, Ann Arbor, USA )
3 Jun 2012
Changing the standard treatment for lymphoma with bendamustine
Dr Mathias Rummel - Universitaetsklinik, Giessen, Germany
Changing the standard treatment for lymphoma with bendamustine ( Dr Mathias Rummel - Universitaetsklinik, Giessen, Germany )
3 Jun 2012
Trastuzumab emtansine improves progression-free survival for HER2-positive breas...
Dr Kimberly Blackwell - Duke University Medical Center, Durham, USA
Trastuzumab emtansine improves progression-free survival for HER2-positive breast cancer ( Dr Kimberly Blackwell - Duke University Medical Center, Durham, USA )
3 Jun 2012
Continuing bevacizumab with second-line chemotherapy for colorectal cancer
Dr Dirk Arnold - University Cancer Center Hamburg, Germany
Continuing bevacizumab with second-line chemotherapy for colorectal cancer ( Dr Dirk Arnold - University Cancer Center Hamburg, Germany )
3 Jun 2012
Combined chemo-radiation extends survival in patients with anaplastic oligodendr...
Dr Martin Van Den Bent - Erasmus University Medical Center, Rotterdam, Netherlan...
Combined chemo-radiation extends survival in patients with anaplastic oligodendroglial tumours ( Dr Martin Van Den Bent - Erasmus University Medical Center, Rotterdam, Netherlands )
3 Jun 2012
Intermittent hormonal therapy less effective than continuous therapy when treati...
Dr Maha Hussain - University of Michigan, Ann Arbor, USA
Intermittent hormonal therapy less effective than continuous therapy when treating advanced prostate cancer ( Dr Maha Hussain - University of Michigan, Ann Arbor, USA )
3 Jun 2012
Lower-income Patients are less likely to participate in clinical trials
Dr Joseph Unger - SWOG Statistical Center, Seattle, USA
Lower-income Patients are less likely to participate in clinical trials ( Dr Joseph Unger - SWOG Statistical Center, Seattle, USA )
3 Jun 2012
Bendamustine regimen more effective for lymphoma than standard CHOP
Dr Mathias Rummel - Universitaetsklinik, Giessen, Germany
Bendamustine regimen more effective for lymphoma than standard CHOP ( Dr Mathias Rummel - Universitaetsklinik, Giessen, Germany )
3 Jun 2012
Early results from new PD-1 targeted immune therapy
Dr Suzanne Topalian - Johns Hopkins University School of Medicine, Baltimore, US...
Early results from new PD-1 targeted immune therapy ( Dr Suzanne Topalian - Johns Hopkins University School of Medicine, Baltimore, USA )
2 Jun 2012
New study asks patients preference on kidney cancer treatment
Dr Bernard Escudier - Institut Gustave Roussy, Paris, France
New study asks patients preference on kidney cancer treatment ( Dr Bernard Escudier - Institut Gustave Roussy, Paris, France )
2 Jun 2012
Relapse and survival of adolescent and young adult leukaemia patients
Dr Eric Larsen - Maine Children’s Cancer Program, Scarborough, USA
Relapse and survival of adolescent and young adult leukaemia patients ( Dr Eric Larsen - Maine Children’s Cancer Program, Scarborough, USA )
2 Jun 2012
Adding bevacizumab to chemotherapy for platinum-resistant ovarian cancer improve...
Dr Eric Pujade-Lauraine - Université Paris Descartes, France
Adding bevacizumab to chemotherapy for platinum-resistant ovarian cancer improves progression-free survival ( Dr Eric Pujade-Lauraine - Université Paris Descartes, France )
2 Jun 2012